Chemical contamination baseline in the Western basin of the Mediterranean sea based on transplanted mussels

The MYTILOS project aimed at drawing up a preliminary report on coastal chemical contamination at the scale of the Western Mediterranean (continental coasts of the Balearic Islands, Sicily, Sardinia, Corsica and Maghreb) based on a transplanted mussels methodology validated along the French coasts since 1996 by Ifremer and the Rhône Méditerranée & Corsica water board. MYTILOS is backed up by the INTERREG III B/MEDOC programme, the PNUE/PAM-MEDPOL and Rhône Méditerranée & Corsica water board. Three cruises (2004, 2005, 2006) have taken place to assess the first state of chemical contamination along the Western Mediterranean shores with the same methodology. Approximately 120 days were spent at sea deploying and retrieving 123 mussel bags. The results obtained for all studied contaminants were equivalent to those obtained along the French coast according the RINBIO network. These similarities relate to both the highest measured levels and background levels throughout the 123 stations. The areas of greatest impact were mainly urban and industrial centers and the outlets of major rivers, with a far higher midsea impact on the dilution of organic compounds than on metals. Metal levels measured in midsea zones were found to be similar to those in natural shellfish populations living along the coast. On a global scale we can observe that the contaminants levels in the Mediterranean Sea are in the same range as in other areas worldwide. Overall, the research demonstrates the reliability of this methodology for marine pollution monitoring, especially in the Mediterranean sea. © 2010 Springer Science+Business Media, LLC.Peer Reviewe

Chemical Contamination Baseline in the Western Basin of the Mediterranean Sea Based on Transplanted Mussels

Publicado

Western Mediterranean coastal waters-Monitoring PCBs and pesticides accumulation in Mytilus galloprovincialis by active mussel watching: the Mytilos project

Publicado

Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.

OBJECTIVE: The objective of this review was to define a core set of recommendations for the treatment of HCV-associated mixed cryoglobulinemia syndrome (MCS) by combining current evidence from clinical trials and expert opinion.METHODS: Expert physicians involved in studying and treating patients with MCS formulated statements after discussing the published data. Their attitudes to treatment approaches (particularly those insufficiently supported by published data) were collected before the consensus conference by means of a questionnaire, and were considered when formulating the statements.RESULTS: An attempt at viral eradication using pegylated interferon plus ribavirin should be considered the first-line therapeutic option in patients with mild-moderate HCV-related MCS. Prolonged treatment (up to 72 weeks) may be considered in the case of virological non-responders showing clinical and laboratory improvements. Rituximab (RTX) should be considered in patients with severe vasculitis and/or skin ulcers, peripheral neuropathy or glomerulonephritis. High-dose pulsed glucocorticoid (GC) therapy is useful in severe conditions and, when necessary, can be considered in combination with RTX; on the contrary, the majority of conference participants discouraged the chronic use of low-medium GC doses. Apheresis remains the elective treatment for severe, life-threatening hyper-viscosity syndrome; its use should be limited to patients who do not respond to (or who are ineligible for) other treatments, and emergency situations. Cyclophosphamide can be considered in combination with apheresis, but the data supporting its use are scarce. Despite the limited available data, colchicine is used by many of the conference participants, particularly in patients with mild-moderate MCS refractory to other therapies. Careful monitoring of the side effects of each drug, and its effects on HCV replication and liver function tests is essential. A low-antigen-content diet can be considered as supportive treatment in all symptomatic MCS patients. Although there are no data from controlled trials, controlling pain should always be attempted by tailoring the treatment to individual patients on the basis of the guidelines used in other vasculitides.CONCLUSION: Although there are few controlled randomised trials of MCS treatment, increasing knowledge of its pathogenesis is opening up new frontiers. The recommendations provided may be useful as provisional guidelines for the management of MCS